DiaMedica Therapeutics Inc.
DMACNasdaq
$7.30
↑ +2.4%Jul 17 close · end-of-day
Price
1Y↑ +83.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$392.7M
Enterprise Value
$341.4M
P/E
—
P/S
—
P/B
8.3
EV/EBITDA
—
PEG
—
FCF Yield
-7.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$35.1M
Free Cash Flow (TTM)
-$31.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-74.3%
ROIC
—
Debt / Equity
—
Net Cash
$51.3M
Return 1Y
+85.8%
Company profile
DiaMedica Therapeutics Inc. develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein. DM199 is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes.
- CEO
- Rick J. Pauls
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Minnesota
- Website
- diamedica.com
Earnings
DMAC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.7M | -$13.6M | -$14.0M | -$21.3M | -$26.7M | -$34.4M |
| Net income | -$12.3M | -$13.6M | -$13.7M | -$19.4M | -$24.4M | -$32.8M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$9.2M | -$12.3M | -$11.5M | -$18.7M | -$22.1M | -$29.1M |
| Free cash flow | -$9.2M | -$12.3M | -$11.6M | -$18.8M | -$22.1M | -$29.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.6M | -$6.9M | -$8.4M | -$8.1M | -$8.0M | -$9.0M | -$9.2M | -$10.5M |
| Net income | -$5.1M | -$6.3M | -$7.9M | -$7.7M | -$7.7M | -$8.6M | -$8.7M | -$10.0M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$4.5M | -$4.5M | -$6.4M | -$7.1M | -$7.6M | -$6.5M | -$7.8M | -$9.1M |
| Free cash flow | -$4.5M | -$4.5M | -$6.4M | -$7.2M | -$7.6M | -$6.6M | -$7.8M | -$9.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
Jun 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-02 | Parsons James T. | Award | 10,095 | $8.42 | $84,999.90 | filing |
| 2026-01-02 | Giuffre Randall Michael | Award | 6,175 | $8.42 | $51,993.50 | filing |
| 2026-01-02 | Semba Charles Pauling | Award | 3,355 | $8.42 | $28,249.10 | filing |
| 2025-11-25 | STAHLBERG JAN | Buy | 73,099 | $8.57 | $626,816.62 | filing |
| 2025-11-24 | STAHLBERG JAN | Buy | 40,253 | $7.89 | $317,720.95 | filing |
| 2025-11-21 | STAHLBERG JAN | Buy | 208,872 | $7.41 | $1.5M | filing |
| 2025-11-21 | Parsons James T. | Option exercise | 12,000 | $2.20 | $26,400.00 | filing |
| 2025-11-20 | STAHLBERG JAN | Buy | 128,426 | $7.41 | $951,212.85 | filing |
| 2025-11-19 | STAHLBERG JAN | Buy | 240,352 | $7.21 | $1.7M | filing |
| 2025-11-18 | STAHLBERG JAN | Buy | 182,882 | $6.75 | $1.2M | filing |
| 2025-11-17 | STAHLBERG JAN | Buy | 187,393 | $6.52 | $1.2M | filing |
| 2025-08-27 | STAHLBERG JAN | Buy | 50,772 | $6.00 | $304,632.00 | filing |
| 2025-08-26 | STAHLBERG JAN | Buy | 59,648 | $6.00 | $357,888.00 | filing |
| 2025-08-25 | STAHLBERG JAN | Buy | 338,265 | $6.00 | $2.0M | filing |
| 2025-08-22 | STAHLBERG JAN | Buy | 59,788 | $5.96 | $356,575.63 | filing |
| 2025-08-21 | STAHLBERG JAN | Buy | 48,172 | $5.96 | $287,028.04 | filing |
| 2025-08-20 | STAHLBERG JAN | Buy | 71,107 | $5.86 | $416,495.03 | filing |
| 2025-08-15 | STAHLBERG JAN | Buy | 8,233 | $6.00 | $49,398.00 | filing |
| 2025-08-14 | STAHLBERG JAN | Buy | 70,414 | $5.99 | $421,920.69 | filing |
| 2025-08-13 | STAHLBERG JAN | Buy | 293,601 | $5.91 | $1.7M | filing |
| 2025-07-23 | Von Koch Thomas | Buy | 2,857,142 | $3.50 | $10.0M | filing |
| 2025-07-23 | STAHLBERG JAN | Buy | 1,542,857 | $3.50 | $5.4M | filing |
| 2025-07-23 | JACINTO RICHARD II | Buy | 400,000 | $3.50 | $1.4M | filing |
Latest 23 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.